GUJTHEMGujarat Themis Biosyn Ltd.
Gujarat Themis Biosyn Q2 FY27 Results: Consolidated Net Loss ₹13.84 Crore on Total Income of ₹53.72 Crore
- Earnings
- Pharmaceutical intermediates and APIs
Gujarat Themis Biosyn (NSE: GUJTHEM) reported a consolidated total income of ₹53.72 crore and a net loss of ₹13.84 crore for the quarter ended 30 Sep 2026, it said in a filing on 14 Nov 2026. Standalone total income was ₹51.13 crore with a net profit of ₹8.47 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹53.72 crore, up 24.5% YoY and 22.3% QoQ
- Net profit and EPS: Net loss of ₹13.84 crore; basic EPS of -₹1.19
- Finance costs: ₹8.36 crore, against ₹0.04 crore a year earlier
- Exceptional item: ₹1.17 crore loss in step-down subsidiary MBJ from an earthquake
Standalone
The company on its own, without its subsidiaries
- Total income: ₹51.13 crore, up 18.4% YoY and 16.4% QoQ
- Net profit and EPS: Net profit of ₹8.47 crore, down 40.6% YoY; basic EPS of ₹0.72
- Finance costs: ₹6.36 crore, against ₹0.04 crore a year earlier
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 53.72 | 43.17 | +24.5% | 43.92 | +22.3% | |
| Revenue from operations | 49.92 | 42.35 | +17.9% | 43.79 | +14.0% |
| Other income | 3.80 | 0.82 | +365.8% | 0.13 | n/a |
| -13.84 | 14.26 | n/a | 11.07 | n/a | |
| Profit before tax | -11.17 | 18.76 | n/a | 15.17 | n/a |
| Finance costs | 8.36 | 0.04 | n/a | 1.79 | +367.5% |
| Depreciation | 4.54 | 2.96 | +53.4% | 3.97 | +14.2% |
| Tax expense | 2.67 | 4.50 | -40.6% | 4.10 | -34.9% |
| Net profit margin | -25.77% | 33.05% | -58.81 pp | 25.20% | -50.96 pp |
| EPS, basic (₹) | -1.19 | 1.31 | n/a | 1.02 | n/a |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated total income grew faster than revenue from operations this quarter. Revenue from operations rose 17.9% YoY to ₹49.92 crore, while other income rose 365.8% to ₹3.80 crore and now makes up 7.1% of total income.
Finance costs moved the most against the year-earlier quarter. They were ₹8.36 crore, or 15.6% of total income, against ₹0.04 crore in Q2 FY26, and depreciation rose 53.4% to ₹4.54 crore. The statement shows the acquisition of MicroBiopharm Japan (MBJ) from 18 Sep 2026, so the quarter includes part of the acquired business, but the figures do not show how much of the cost came from it.
The consolidated pre-tax result is a loss of ₹11.17 crore. The notes name two items within other expenditure and the exceptional line: an exceptional loss of ₹1.17 crore at MBJ, which the notes say arose from an earthquake, and extraordinary unrealised foreign conversion losses of ₹15.57 crore. Net loss after tax of ₹13.84 crore compares with a net profit of ₹14.26 crore a year earlier. Consolidated EPS was -₹1.19 against ₹1.31.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 51.13 | 43.17 | +18.4% | 43.92 | +16.4% | |
| Revenue from operations | 47.45 | 42.35 | +12.0% | 43.79 | +8.4% |
| Other income | 3.68 | 0.82 | +348.8% | 0.13 | n/a |
| 8.47 | 14.27 | -40.6% | 11.07 | -23.5% | |
| Finance costs | 6.36 | 0.04 | n/a | 1.79 | +255.3% |
| Depreciation | 3.99 | 2.96 | +34.8% | 3.97 | +0.5% |
| Tax expense | 2.59 | 4.50 | -42.4% | 4.10 | -36.8% |
| Net profit margin | 16.57% | 33.06% | -16.49 pp | 25.20% | -8.64 pp |
| Tax as share of profit before tax | 23.4% | 24.0% | -0.55 pp | 27.0% | -3.59 pp |
| EPS, basic (₹) | 0.72 | 1.31 | -45.0% | 1.02 | -29.4% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit fell 40.6% YoY to ₹8.47 crore while total income rose 18.4%. Standalone revenue from operations rose 12.0% to ₹47.46 crore, slower than other income, which rose 348.8% to ₹3.68 crore and equals 33.3% of standalone profit before tax of ₹11.05 crore.
Standalone tax expense of ₹2.59 crore is 23.4% of profit before tax, close to the year-earlier 24.0%. Finance costs of ₹6.36 crore are 12.4% of total income this quarter. The standalone statement reports no exceptional item for the quarter.
Consolidated net profit of -₹13.84 crore is ₹22.31 crore lower than standalone net profit of ₹8.47 crore. The consolidated statement includes MBJ from 18 Sep 2026 and the exceptional and foreign conversion items noted above.
The company says it operates in one business segment, manufacturing fermentation-based pharmaceutical intermediates and APIs. The company also issued 58,500 NCDs aggregating ₹585 crore on a private placement basis on 15 and 16 Sep 2026.
Inference
The filing says the QIP proceeds are to support inorganic growth, including investment or loans in the subsidiary Themis Biosyn Japan, and for general corporate purposes. The filing says the auditors gave an unmodified conclusion on both statements, but drew attention to consolidated comparative figures for Q2 FY26 and 31 Mar 2026 that were not reviewed.
The filing does not say how the earthquake loss at MBJ will be recovered or insured, what the final goodwill amount will be after the purchase price allocation, or why finance costs rose so sharply. Company Secretary Vineet Gawankar resigned with effect from 30 Nov 2026 to pursue opportunities outside the organisation.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.